Risk-adapted Therapeutic Strategy in +1q NDMM

This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.

NCT Number	NCT07045168
Lead Sponsor	FengYan Jin
Conditions	Multiple Myeloma
Enrollment	200 participants
Start Date	2025-09-15
Primary Completion	2027-09-15 (estimated)
Study Completion	2029-07-04 (estimated)
Updated on ClinicalTrials.gov	2025-09-15